These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 35300091)

  • 1. Development of Myostatin Inhibitory d-Peptides to Enhance the Potency, Increasing Skeletal Muscle Mass in Mice.
    Takayama K; Hitachi K; Okamoto H; Saitoh M; Odagiri M; Ohfusa R; Shimada T; Taguchi A; Taniguchi A; Tsuchida K; Hayashi Y
    ACS Med Chem Lett; 2022 Mar; 13(3):492-498. PubMed ID: 35300091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enzymatic Stability of Myostatin Inhibitory 16-mer Peptides.
    Takayama K; Odagiri M; Taguchi A; Taniguchi A; Hayashi Y
    Chem Pharm Bull (Tokyo); 2020; 68(6):512-515. PubMed ID: 32475853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and synthesis of potent myostatin inhibitory cyclic peptides.
    Rentier C; Takayama K; Saitoh M; Nakamura A; Ikeyama H; Taguchi A; Taniguchi A; Hayashi Y
    Bioorg Med Chem; 2019 Apr; 27(7):1437-1443. PubMed ID: 30777663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Medicinal Chemistry Focused on Mid-sized Peptides Derived from Biomolecules].
    Takayama K
    Yakugaku Zasshi; 2019; 139(11):1377-1384. PubMed ID: 31685733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of the minimum region of flatfish myostatin propeptide (Pep45-65) for myostatin inhibition and its potential to enhance muscle growth and performance in animals.
    Kim JH; Kim JH; Sutikno LA; Lee SB; Jin DH; Hong YK; Kim YS; Jin HJ
    PLoS One; 2019; 14(4):e0215298. PubMed ID: 30998775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of N-Terminal Acylation on the Activity of Myostatin Inhibitory Peptides.
    Takayama K; Nakamura A; Rentier C; Mino Y; Asari T; Saga Y; Taguchi A; Yakushiji F; Hayashi Y
    ChemMedChem; 2016 Apr; 11(8):845-9. PubMed ID: 26954624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chain-Shortened Myostatin Inhibitory Peptides Improve Grip Strength in Mice.
    Takayama K; Asari T; Saitoh M; Nirasawa K; Sasaki E; Roppongi Y; Nakamura A; Saga Y; Shimada T; Ikeyama H; Taguchi A; Taniguchi A; Negishi Y; Hayashi Y
    ACS Med Chem Lett; 2019 Jun; 10(6):985-990. PubMed ID: 31223459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategic structure-activity relationship study on a follistatin-derived myostatin inhibitory peptide.
    Saitoh M; Takayama K; Roppongi Y; Shimada T; Taguchi A; Taniguchi A; Hayashi Y
    Bioorg Med Chem Lett; 2021 Aug; 46():128163. PubMed ID: 34087433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination therapy with anamorelin and a myostatin inhibitor is advantageous for cancer cachexia in a mouse model.
    Hanada K; Fukasawa K; Hinata H; Imai S; Takayama K; Hirai H; Ohfusa R; Hayashi Y; Itoh F
    Cancer Sci; 2022 Oct; 113(10):3547-3557. PubMed ID: 35849084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of a follistatin-derived myostatin inhibitory peptide.
    Saitoh M; Takayama K; Hitachi K; Taguchi A; Taniguchi A; Tsuchida K; Hayashi Y
    Bioorg Med Chem Lett; 2020 Feb; 30(3):126892. PubMed ID: 31874826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A mouse anti-myostatin antibody increases muscle mass and improves muscle strength and contractility in the mdx mouse model of Duchenne muscular dystrophy and its humanized equivalent, domagrozumab (PF-06252616), increases muscle volume in cynomolgus monkeys.
    St Andre M; Johnson M; Bansal PN; Wellen J; Robertson A; Opsahl A; Burch PM; Bialek P; Morris C; Owens J
    Skelet Muscle; 2017 Nov; 7(1):25. PubMed ID: 29121992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increasing Skeletal Muscle Mass in Mice by Non-Invasive Intramuscular Delivery of Myostatin Inhibitory Peptide by Iontophoresis.
    Michiue K; Takayama K; Taniguchi A; Hayashi Y; Kogure K
    Pharmaceuticals (Basel); 2023 Mar; 16(3):. PubMed ID: 36986496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myostatin gene deletion prevents glucocorticoid-induced muscle atrophy.
    Gilson H; Schakman O; Combaret L; Lause P; Grobet L; Attaix D; Ketelslegers JM; Thissen JP
    Endocrinology; 2007 Jan; 148(1):452-60. PubMed ID: 17038559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peptide Tool-Driven Functional Elucidation of Biomolecules Related to Endocrine System and Metabolism.
    Takayama K
    Chem Pharm Bull (Tokyo); 2022; 70(6):413-419. PubMed ID: 35650039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myostatin inhibition in combination with antisense oligonucleotide therapy improves outcomes in spinal muscular atrophy.
    Zhou H; Meng J; Malerba A; Catapano F; Sintusek P; Jarmin S; Feng L; Lu-Nguyen N; Sun L; Mariot V; Dumonceaux J; Morgan JE; Gissen P; Dickson G; Muntoni F
    J Cachexia Sarcopenia Muscle; 2020 Jun; 11(3):768-782. PubMed ID: 32031328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Inhibitory Core of the Myostatin Prodomain: Its Interaction with Both Type I and II Membrane Receptors, and Potential to Treat Muscle Atrophy.
    Ohsawa Y; Takayama K; Nishimatsu S; Okada T; Fujino M; Fukai Y; Murakami T; Hagiwara H; Itoh F; Tsuchida K; Hayashi Y; Sunada Y
    PLoS One; 2015; 10(7):e0133713. PubMed ID: 26226340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MIF1 and MIF2 Myostatin Peptide Inhibitors as Potent Muscle Mass Regulators.
    Lee EJ; Shaikh S; Baig MH; Park SY; Lim JH; Ahmad SS; Ali S; Ahmad K; Choi I
    Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of the minimum peptide from mouse myostatin prodomain for human myostatin inhibition.
    Takayama K; Noguchi Y; Aoki S; Takayama S; Yoshida M; Asari T; Yakushiji F; Nishimatsu S; Ohsawa Y; Itoh F; Negishi Y; Sunada Y; Hayashi Y
    J Med Chem; 2015 Feb; 58(3):1544-9. PubMed ID: 25569186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myostatin inhibition by a follistatin-derived peptide ameliorates the pathophysiology of muscular dystrophy model mice.
    Tsuchida K
    Acta Myol; 2008 Jul; 27(1):14-8. PubMed ID: 19108572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of Potent Myostatin Inhibitory Peptides through Hydrophobic Residue-Directed Structural Modification.
    Takayama K; Rentier C; Asari T; Nakamura A; Saga Y; Shimada T; Nirasawa K; Sasaki E; Muguruma K; Taguchi A; Taniguchi A; Negishi Y; Hayashi Y
    ACS Med Chem Lett; 2017 Jul; 8(7):751-756. PubMed ID: 28740611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.